Stay updated on Open-Label Surufatinib in EU NET Patients Clinical Trial

Sign up to get notified when there's something new on the Open-Label Surufatinib in EU NET Patients Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Open-Label Surufatinib in EU NET Patients Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.
    Difference
    0.1%
    Check dated 2025-05-01T06:27:34.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    The page has undergone significant content changes, including the removal of detailed information about a Phase 2 study of surufatinib for neuroendocrine tumors, and the addition of a new revision number.
    Difference
    25%
    Check dated 2025-04-16T20:35:54.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to March 20, 2025.
    Difference
    0.3%
    Check dated 2025-04-09T14:48:31.000Z thumbnail image
  6. Check
    44 days ago
    Change Detected
    Summary
    The page has been updated to reflect a new timeline for the Open-Label Phase 2 Study of Surufatinib in European Patients with Neuroendocrine Tumours, with new dates for the study and the removal of previous recruitment statuses.
    Difference
    3%
    Check dated 2025-03-25T17:44:52.000Z thumbnail image
  7. Check
    73 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    2%
    Check dated 2025-02-24T23:20:17.000Z thumbnail image
  8. Check
    88 days ago
    Change Detected
    Summary
    The web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    2%
    Check dated 2025-02-10T17:05:52.000Z thumbnail image

Stay in the know with updates to Open-Label Surufatinib in EU NET Patients Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Open-Label Surufatinib in EU NET Patients Clinical Trial page.